(77 days)
Not Found
No
The description details a standard clinical chemistry assay based on a chemical reaction and spectrophotometric measurement, with no mention of AI or ML.
No.
This device is an in vitro diagnostic assay used for the quantitative determination of inorganic phosphorus, which aids in the diagnosis and treatment of disorders, rather than directly treating a condition.
Yes
The "Intended Use / Indications for Use" section explicitly states that "Measurements of phosphorus (inorganic) are used in the diagnosis and treatment of various disorders." This indicates that the device provides information for diagnostic purposes.
No
The device description clearly states it is an "in vitro diagnostic assay" and describes a chemical reaction and measurement at a specific wavelength (340 nm), indicating it is a laboratory test that requires physical reagents and instrumentation, not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The description explicitly states the assay is used for the "quantitation of inorganic phosphorus in human serum, plasma, or urine" and that these measurements are used in the "diagnosis and treatment of various disorders". This clearly indicates the device is intended for use on specimens derived from the human body to provide information for diagnostic purposes.
- Device Description: The description further clarifies that the Phosphorus assay is an "in vitro diagnostic assay" and describes the chemical reaction that occurs in vitro (outside the body) to measure the phosphorus.
The document consistently uses language and provides information that aligns with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Phosphorus assay is used for the quantitation of inorganic phosphorus in human serum, plasma, or urine. Measurements of phosphorus (inorganic) are used in the diagnosis and treatment of various disorders, including parathyroid gland and kidney diseases, and vitamin D imbalance.
Product codes
75CEO
Device Description
Phosphorus is an in vitro diagnostic assay for the quantitative determination of inorganic phosphorus in human serum, plasma, or urine. The Phosphorus assay is a clinical chemistry assay in which the inorganic phosphorus reacts with ammonium molybdate in dilute sulfuric acid to form the unreduced phosphomolybdate complex. The formation of the unreduced phosphomolybdate is measured at 340 nm and is directly proportional to the amount of inorganic phosphorus present.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Comparative performance studies were conducted using the ALCYON™ Analyzer. The Phosphorus assay method comparison yielded acceptable correlation with the Roche Cobas Mira Plus Automated Chemistry System Phosphorus assay for the serum application and the Boehringer Mannheim Phosphorus assay on the Hitatchi 717 Analyzer for the urine application. For the serum application, the correlation coefficient = 0.9885, slope = 1.049, and the Y-intercept = 0.264 mg/dL. For the urine application, the correlation coefficient = 0.9947, slope = 0.973, and Y-intercept = - 1.582 mg/dL. Precision studies were conducted using the Phosphorus assay. Within-run, between-run, and between-day studies were performed using two levels of control material. For the serum application, the total %CV for Level 1/Panel 111 control is 2.8% and Level 2/Panel 112 is 2.7%. For the urine application, the total %CV for Level 1/Panel 111 control is 3.2% and Level 2/Panel 112 is 2.4%. The Phosphorus assay is linear up to 16 mg/dL. The limit of quantitation (sensitivity) of the Phosphorus assay is 0.3 mg/dL.
Key Metrics
For the serum application, the correlation coefficient = 0.9885, slope = 1.049, and the Y-intercept = 0.264 mg/dL. For the urine application, the correlation coefficient = 0.9947, slope = 0.973, and Y-intercept = - 1.582 mg/dL. For the serum application, the total %CV for Level 1/Panel 111 control is 2.8% and Level 2/Panel 112 is 2.7%. For the urine application, the total %CV for Level 1/Panel 111 control is 3.2% and Level 2/Panel 112 is 2.4%. The Phosphorus assay is linear up to 16 mg/dL. The limit of quantitation (sensitivity) of the Phosphorus assay is 0.3 mg/dL.
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1580 Phosphorus (inorganic) test system.
(a)
Identification. A phosphorus (inorganic) test system is a device intended to measure inorganic phosphorus in serum, plasma, and urine. Measurements of phosphorus (inorganic) are used in the diagnosis and treatment of various disorders, including parathyroid gland and kidney diseases, and vitamin D imbalance.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
Image /page/0/Picture/0 description: The image shows a sequence of handwritten characters and numbers. The sequence appears to be 'K981118'. The characters are written in a bold, somewhat irregular style, giving them a distinct, hand-drawn appearance. The contrast between the characters and the background is high, making them easily readable.
510(k) Summary
Submitter's Name/Address
Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038 Contact Person Mark Littlefield Section Manager MS 1-8 Regulatory Affairs (972) 518-7861 Fax (972) 753-3367
| Date of Preparation of this Summary: | March 26, 1998 |
|---|---|
| Device Trade or Proprietary Name: | Phos |
| Device Common/Usual Name or Classification Name: | Phosphorus |
| Classification Number/Class: | 75CEO/Class I |
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is:
Test Description:
Phosphorus is an in vitro diagnostic assay for the quantitative determination of inorganic phosphorus in human serum, plasma, or urine. The Phosphorus assay is a clinical chemistry assay in which the inorganic phosphorus reacts with ammonium molybdate in dilute sulfuric acid to form the unreduced phosphomolybdate complex. The formation of the unreduced phosphomolybdate is measured at 340 nm and is directly proportional to the amount of inorganic phosphorus present.
Substantial Equivalence:
The Phosphorus assay is substantially equivalent to the following devices:
- . Roche® Cobas Mira® Plus Phosphorus assay (K883962) for the serum application
- . Boehringer Mannheim® Phosphorus Assay (K872494) on the Hitachi® 717 Analyzer for the urine application
Phosphorus 510(k) March 26, 1998 Phos326.lwg
Section II Page 1
Image /page/0/Picture/16 description: The image shows the number 000012 in a bold, sans-serif font. The numbers are all black and are set against a white background. The numbers are evenly spaced and are all the same size. The image is clear and easy to read.
1
These assays yield similar Performance Characteristics.
Similarities to Roche:
- Both assays are in vitro clinical chemistry methods. .
- Both assays can be used for the quantitative determination of inorganic . phosphorus.
- Both assays yield similar clinical results. .
Differences to Roche:
-
There is a minor difference in the assay range. .
Similarities to Boehringer Mannheim: -
Both assays are in vitro clinical chemistry methods. .
-
Both assays can be used for the quantitative determination of inorganic . phosphorus.
-
. Both assays vield similar clinical results.
Differences to Boehringer Mannheim:
- . There is a minor difference in the assay range.
Intended Use:
The Phosphorus assay is used for the quantitation of inorganic phosphorus in human serum, plasma, or urine.
Performance Characteristics:
Comparative performance studies were conducted using the ALCYON™ Analyzer. The Phosphorus assay method comparison yielded acceptable correlation with the Roche Cobas Mira Plus Automated Chemistry System Phosphorus assay for the serum application and the Boehringer Mannheim Phosphorus assay on the Hitatchi 717 Analyzer for the urine application. For the serum application, the correlation coefficient = 0.9885, slope = 1.049, and the Y-intercept = 0.264 mg/dL. For the urine application, the correlation coefficient = 0.9947, slope = 0.973, and
Phosphorus 510(k) March 26, 1998 Phos326.lwp
Section II Page 2
Image /page/1/Picture/19 description: The image shows the number 0000013 in a bold, sans-serif font. The numbers are black and stand out against a white background. The numbers are evenly spaced and aligned horizontally. The number is likely a serial number or identification code.
2
Y-intercept = - 1.582 mg/dL. Precision studies were conducted using the Phosphorus assay. Within-run, between-run, and between-day studies were performed using two levels of control material. For the serum application, the total %CV for Level 1/Panel 111 control is 2.8% and Level 2/Panel 112 is 2.7%. For the urine application, the total %CV for Level 1/Panel 111 control is 3.2% and Level 2/Panel 112 is 2.4%. The Phosphorus assay is linear up to 16 mg/dL. The limit of quantitation (sensitivity) of the Phosphorus assay is 0.3 mg/dL. These data demonstrate that the performance of the Phosphorus assay is substantially equivalent to the performance of the Roche Cobas Mira Plus Automated Chemistry System Phosphorus assay for the serum application and the Boehringer Mannheim Phosphorus assay on the Hitatchi 717 Analyzer for the urine application.
Conclusion:
The Phosphorus assay is substantially equivalent to the Roche Cobas Mira Plus Automated Chemistry System Phosphorus assay for the serum application and the Boehringer Mannheim Phosphorus assay on the Hitatchi 717 Analyzer for the urine application as demonstrated by results obtained in the studies.
Phosphorus 510(k) March 26, 1998 Phos326.lwp
Section II Page 3
Image /page/2/Picture/5 description: The image shows the number 0000014 in a bold, sans-serif font. The numbers are black against a white background. The numbers are evenly spaced and aligned horizontally.
3
Image /page/3/Picture/1 description: The image is a black and white logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three lines forming its body and wings. The eagle is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
JUN 12 1998
Mark Littlefield Section Manager, Regulatory Affairs Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038
K981118 Re : Phosphorus I Regulatory Class: Product Code: CEO Dated: March 26, 1998 Received: March 27, 1998
Dear Mr. Littlefield:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. ಗಿ substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
4
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Litman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
Device Name: Phosphorus
Indications For Use:
The Phosphorus assay is used for the quantitation of inorganic phosphorus in human serum, plasma, or urine. Measurements of phosphorus (inorganic) are used in the diagnosis and treatment of various disorders, including parathyroid gland and kidney diseases, and vitamin D imbalance.
Lision. Clore. 0.62
(Division Sign-Off) Division of Clinical Laboratory Defices 510(k) Number .
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
ﻨﺴﺎ Prescription Use (Per 21 CFR 801.109)
OR
Over-The-Counter Use -----
(Optional Format 1-2-96)
00000006